Committed to academic medicine
As an interdisciplinary team, we support patients with oncological diseases at all stages with precise diagnostics, individually tailored therapies and high-quality, empathetic care.
State-of-the-art cancer medicine – individual, interdisciplinary, internationally recognized
The Central European Cancer Center at Wiener Privatklinik is one of the leading private cancer centers in Central and Southeastern Europe. What sets us apart:
- High-end medicine by interdisciplinary teams with internationally recognized specialists
- Precise tumor diagnostics with state-of-the-art technologies such as PET-CT, molecular pathology and interventional radiology
- Regular tumor boards with experts from surgery, oncology, urology, gynecology and other disciplines
- Individual treatment decisions based on medical excellence and experience
- Fast access to innovative therapies thanks to short approval processes in Austria
Humanity that makes the difference
We are convinced that the best cancer medicine needs more than just technology – it also needs proximity, trust and time. That’s why we at Wiener Privatklinik focus on:
- Individual support instead of anonymous processes
- Joint decisions instead of standard processes
- Personal contact persons – often in the native language of our patients
- Appreciation and discretion in a protected, exclusive environment
Our promise: cutting-edge medicine with heart – because people matter.
Publications
ESMO-Magnitude of Clinical Benefit Scale
The ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated tool to assess the magnitude of clinical benefit from new cancer therapies, with planned updates based upon recognition of new needs and shortcomings.
View publication
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection
Asian, Black, and Hispanic men are underrepresented in prostate cancer (PCa) clinical trials. Few novel prostate cancer biomarkers have been validated in diverse cohorts. We aimed to determine if Stockholm3 can improve prostate cancer detection in a diverse cohort.
View publication
Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancers
The rising incidence of multiple lung cancers (MLCs), encompassing multiple primary lung cancers (MPLCs) and intrapulmonary metastasis (IPM), poses two significant clinical challenges. First, distinguishing between MPLC and IPM remains difficult due to insufficiently accurate criteria and ambiguous integration of genetic testing. Second, standardized therapeutic protocols are still lacking.
View publication